Tonix Pharmaceuticals News and Activities

Tonix Pharmaceuticals is a company listed under the stock ticker TNXP (US).

View the org chart displaying its 31 main executives

Most searched biographies at Tonix Pharmaceuticals

• Seth Lederman, Co-Founder, Chairman and Chief Executive Officer
• Carolyn Taylor, Director
• Adeoye Olukotun, Director

Popular executive movements at Tonix Pharmaceuticals

• Irina Ishak has joined the company as General Counsel  (posted on December 10 2025).
• Ganesh Kamath has joined the company as Head, Market Access  (posted on October 1 2025).

Create your alert
to follow the executive moves at Tonix Pharmaceuticals.

Tonix Pharmaceuticals has 1,913 competitors including Sanofi (France), Eli Lilly (United States (USA)) and Moderna (United States (USA)).

Popular M&A news in Pharmaceuticals

• Laboratoire Servier has announced the acquisition of Edgewise Therapeutics  (posted on June 4 2026).
• Contraline has just announced a $93 Million fundraising (posted on June 3 2026).
• Hims & Hers has acquired Eucalyptus (posted on June 2 2026).

Popular contacts in Pharmaceuticals

• Joaquin Duato - Chief Executive Officer and Chairman of the Board at Johnson & Johnson
• Richard Saynor - Chief Executive Officer at Sandoz
• Robert Ford - Chief Executive Officer and Chairman of the Board at Abbott

Learn more about the Pharmaceuticals industry

Press releases by Tonix Pharmaceuticals

• Tonix Pharmaceuticals Announces Publication of Phase 1 Clinical Data of TNX-1500, an Fc-Modified anti-CD40L (CD154) Monoclonal Antibody, in the Peer-Reviewed Journal of Clinical Immunology
• Tonix Pharmaceuticals Presented Retrospective U.S. Real-World Claims Analysis of Opioid Use in Patients with Fibromyalgia at the 2026 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting
• Tonix Pharmaceuticals Presented Retrospective U.S. Real-World Claims Analysis Characterizing Patients with Fibromyalgia at The Professional Society for Health Economics and Outcomes Research (ISPOR) 2026 Annual Meeting
• Tonix Pharmaceuticals Reports First Quarter 2026 Financial Results and Operational Highlights
• Tonix Pharmaceuticals to Participate in Two Investor Conferences in May
• Tonix Pharmaceuticals to Present Retrospective U.S. Real-World Claims Analysis Characterizing Patients with Fibromyalgia at ISPOR 2026
• Tonix Pharmaceuticals Secures Commercial Payer Coverage for TONMYA®, Providing Access for ~35 Million U.S. Patients
• Tonix Pharmaceuticals Announces Presentation of Phase 1 Data and Plans for an Adaptive Phase 2 Field Study of TNX-4800 (anti-Borrelia OspA monoclonal antibody) for the Prevention of Lyme Disease at the 4th Annual Ticks and Tickborne Diseases Symposium at
• Tonix Pharmaceuticals Presents Updates on Preclinical Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2026
• Tonix Pharmaceuticals Announces Publication of Steady-State Pharmacokinetics of TONMYA® After 20 Days of Daily Dosing in the Peer-Reviewed Journal, Clinical Pharmacology in Drug Development
• View more press releases Close

Social media about Tonix Pharmaceuticals

• Tonix Pharmaceuticals on Wikipedia, Google News & Yahoo Finance
• Tonix Pharmaceuticals on LinkedIn, X (Twitter) & YouTube